Proxy Votes Now

Home › Funds › Virtus Biotech ETF

Virtus Biotech ETF (BBP) proxy voting record 2025-2026

Fund family: ETFis Series Trust I · Filed by ETFis Series Trust I (CIK 1559109) · SEC series S000047354

Ticker: BBP (C000148682)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 496 with, 5 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other ETFis Series Trust I funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 94.0% of this fund’s 501 such votes could be given a sector; the other 30 (6.0%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care47151.1%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2900
Audit-related640
Say-on-Pay610
Compensation490
Corporate Governance233
Capital Structure150
Extraordinary Transactions20
Other Social Issues21
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.May 6, 2026$11M50
Iovance Biotherapeutics, Inc.June 10, 2026$6M120
TG Therapeutics, Inc.June 11, 2026$4M80
Moderna, Inc.November 12, 2025$3M20
BeOne Medicines Ltd.June 11, 2026$3M320
Ligand Pharmaceuticals IncorporatedJune 5, 2026$3M110
Exelixis, Inc.May 26, 2026$3M140
Biogen Inc.June 9, 2026$3M120

Notable votes against management

MeetingCompanyProposalFundMgmt
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst

Search this fund’s votes by company

507 ballot items at 60 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Virtus Biotech ETF (BBP) voted at 60 shareholder meetings of 59 companies, on 507 ballot items in all. Where management made a recommendation, the fund followed it on 99.0% of the items and voted against it 5 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 5 shareholder proposals.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.